info@seagull-health.com
SeagullHealth
search
Ritlecitinib(Litfulo)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Litfulo(Ritlecitinib) Instructions:Uses,Dosage, Side Effects
Ritlecitinib was developed by Pfizer, an American pharmaceutical company. It was approved for marketing by the U.S. FDA on June 23, 2023. In China, ritlecitinib was approved for marketing on October 18, 2023.
Ritlecitinib has not been explicitly included in China's National Medical Insurance Catalog. Patients may need to purchase the drug at their own expense or alleviate the financial burden through other medical insurance plans, drug subsidy programs, or preferential programs offered by pharmaceutical companies.
It is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents aged 12 years and older. Combination use with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants is not recommended.
(1) The recommended dosage of litoxetine is 50 mg, taken orally once daily, with or without food.
(2) Swallow the capsule whole. Do not crush, split, or chew the litoxetine capsule.
(3) If a dose is missed, take it as soon as possible unless it is less than 8 hours until the next scheduled dose, in which case the missed dose should be skipped. Resume administration at the regular time thereafter.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
